
MGTX Stock Forecast & Price Target
MGTX Analyst Ratings
Bulls say
MeiraGTx Holdings is a promising biotechnology company with a diverse pipeline and strong in-house manufacturing capabilities. The company's recent financing deal with Oberland Capital provides additional funds to support development and commercialization activities for its lead programs in xerostomia and retinal diseases. Risks to the outlook include delays in advancing pipeline candidates and potential dilution of equity. However, the company's focus on sustainable and ethical practices, as well as its collaborations with patient support groups, demonstrate its commitment to making a positive impact in the healthcare industry.
Bears say
MeiraGTx Holdings is a clinical-stage genetic medicines company operating in the United States, the United Kingdom, and the European Union. Despite its focus on developing targeted therapies for diseases with high unmet needs, the company has a history of ongoing net losses and faces risks such as clinical program execution, regulatory uncertainties, and competition. Its recent strategic partnership for its Parkinson's program may provide some financial relief, but the company's speculative nature and unpredictable future revenues and expenses warrant a negative outlook.
This aggregate rating is based on analysts' research of MeiraGTx Holdings plc and is not a guaranteed prediction by Public.com or investment advice.
MGTX Analyst Forecast & Price Prediction
Start investing in MGTX
Order type
Buy in
Order amount
Est. shares
0 shares